Lilly’s donanemab could bring new hope to Alzheimer’s patients in Australia following lecanemab…
Australia’s Alzheimer’s patients await potential treatment shift as TGA reviews Lilly’s donanemab following lecanemab rejection
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Eli Lilly’s
Viking Therapeutics’ obesity drug could become direct competitor to Eli Lilly’s tirzepatide:…
With promising Phase IIa results and a dual GLP-1/GIP receptor mechanism, VK2735 could soon compete directly with tirzepatide in…
FDA approves Eli Lilly’s alzheimer’s drug
The drug is targeted at adults in the mild cognitive impairment or mild dementia stage